Brain amyloid imaging—FDA approval of florbetapir F18 injection
In 2012, the FDA approved florbetapir F18 (Amyvid), a radioactive diagnostic agent for positron emission tomography (PET) imaging to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. A negative scan indicates sparse to no neuritic
June 26, 2025
No Comments